Monthly Archives: February 2020
VUMC in the news
A roundup of a few recent stories from the press about Vanderbilt University Medical Center. Continue reading
Work-Life Connections EAP offers support in observance of Eating Disorder Awareness Month
“Momentum”: From research to remedy
Ishmeal Boles was so sick with cancer he was out of his mind. His lung cancer, which had gone undiagnosed, had spread to his liver, spine and brain when he was transferred from a community hospital to Vanderbilt University Medical Center. Continue reading
Reminder: App offers GPS tracking of Vanderbilt shuttles
Riders accustomed to following the progress of an Uber or Lyft ride can have a similar experience with Vanderbilt shuttles. Passengers can track the locations of all Vanderbilt shuttles using the Passio Go app, which is downloadable to most smartphones. Continue reading
Study examines how to best help patients breathe after trauma
Emergency Medicine and Trauma Surgery researchers at Vanderbilt University Medical Center are joining the Nashville Fire Department and nearly two dozen emergency medical service agencies across the country in a Department of Defense (DOD)-funded clini… Continue reading
Remembering Stanley Cohen, Vanderbilt’s elusive Nobel Prize winner
Stanley Cohen wanted to be left alone to do his research. I wanted to interview him for a radio show. Amazingly, he said yes. Continue reading
NFL Hall-of-Famer Raymond Berry wears Heart and Vascular Institute tie at Super Bowl
National Football League Hall of Fame wide receiver Raymond Berry was honored at the Super Bowl and made sure he wore a special necktie for the occasion, one designed for the Vanderbilt Heart and Vascular Institute. Continue reading
Team tracks integrin’s role in lung function
Beta-1 integrin, a critical component of epithelial extracellular matrix receptors, is essential for normal lung function in adulthood, researchers at Vanderbilt University Medical Center have discovered. Continue reading
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
We evaluated the efficacy and safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, in a randomized trial of patients with Crohn’s disease (CD). Continue reading